The Conversation (0)
Sernova (TSX-V:SVA) (FSE:PSH) has announced a licence agreement with the University Health Nework of Toronto, securing worldwide commercial rights to proprietary stem cell derived technologies developed by distinguished UHN researchers Dr. Christina Nostro and Dr. Gorden Keller.
Sernova (TSX-V:SVA) (FSE:PSH) has announced a licence agreement with the University Health Nework of Toronto, securing worldwide commercial rights to proprietary stem cell derived technologies developed by distinguished UHN researchers Dr. Christina Nostro and Dr. Gorden Keller.
Dr. Philip Toleikis, Sernova’s President and CEO, said:
This agreement provides us with a proprietary source of stem cell derived glucose responsive therapeutic cells. When placed within Sernova’s prevascularized Cell Pouch(TM), and protected locally from immune system attack, we believe that Sernova has the potential to provide a significant break-through in the quality of treatment for the millions of people suffering from insulin-dependent diabetes. Such individuals could essentially be liberated from their current onerous daily regime of multiple blood glucose testing and insulin administration delivered through injections or electronic means which is expected to materially improve their quality of life, prevent or reduce abnormal glucose complications, and reduce short term and longer term health care costs.
Click here to read the full press release from Sernova.